Atorvastatin treatment improves effects of implanted mesenchymal stem cells: meta-analysis of animal models with acute myocardial infarction.
Atorvastatin treatment improves effects of implanted mesenchymal stem cells: meta-analysis of animal models with acute myocardial infarction.
复制标题
阿托伐他汀治疗可改善植入间充质干细胞的效果：急性心肌梗死动物模型的荟萃分析
DOI：
10.1186/s12872-015-0162-6
复制
发表时间：
2015-12-14
影响因子：
2.1
通讯作者：
Wu X
中科院分区：
文献类型：
--
作者：
Dai G;Xu Q;Luo R;Gao J;Chen H;Deng Y;Li Y;Wang Y;Yuan W;Wu X
背景既往研究报道阿托伐他汀（ATOR）可以提高急性心肌梗死（AMI）后间充质干细胞（MSC）移植的疗效。然而，这些研究的结果并不一致。为阐明阿托伐他汀联合骨髓间充质干细胞治疗急性心肌梗死（AMI）动物模型的有益作用，我们对病例对照研究进行了系统评价和荟萃分析。方法检索PubMed数据库、Embase数据库、Science Citation Index、中国知网数据库、万方数据库、中文科技期刊数据库（VIP数据库）。检索词包括“阿托伐他汀（或Ator）"、“间充质干细胞（或间充质干细胞或MSC或MSC）”和“急性心肌梗死（或心肌梗死或AMI或MI）"。研究终点为AMI动物模型的左心室射血分数（LVEF）。合并分析显示，随访4周时，MSCs + ATOR联合收割机组与MSCs单独组之间的LVEF差异显著（95%CI，9.09- 13.62%;P< 0.01），具有异质性（P= 0.28;P>0.05）和不一致性（I2：结论阿托伐他汀可增强骨髓间充质干细胞移植的既存效应，并且这种组合疗法是一种上级细胞/药理学治疗方法，值得将来进行临床前和临床研究。
BackgroundPrevious studies reported that Atorvastatin (ATOR) can improve the efficacy of Mesenchymal stem cells (MSCs) transplantation after acute myocardial infarction (AMI). However, the results of those studies were inconsistent. To clarify the beneficial effects of atorvastatin added to the cell therapy with MSCs in animal model of acute myocardial infarction (AMI), we performed a systematic review and meta-analysis of case–control studies.MethodsSearches were performed using the PubMed database, the Excerpta Medica Database (Embase), the Science Citation Index, the China National Knowledge Information database, the Wanfang database, and the Chinese Scientific and Technological Journal Database (VIP database). The search term included “Atorvastatin (or Ator)”, “Mesenchymal Stem Cells (or Mesenchymal Stem Cell or MSC or MSCs)” and “Acute Myocardial Infarction (or Myocardial Infarction or AMI or MI)”. The endpoints were the left ventricular ejection fraction (LVEF) in animal model with AMI.ResultsIn total, 5 studies were included in the meta-analysis. Pooled analysis indicated a significant LVEF difference at 4 weeks follow-up between MSCs + ATOR combine group and MSCs alone group (95 % CI, 9.09–13.62 %;P< 0.01) with heterogeneity (P= 0.28;P>0.05) and inconsistency (I2: 22 %).ConclusionsAtorvastatin can enhance the existing effects of MSCs transplantation, and this combinational therapy is a superior cell/pharmacological therapeutic approach that merits future preclinical and clinical studies.